Amgen Investing $550M in New Biomanufacturing Facility

Amgen has unveiled plans to build a new $550 million biologics manufacturing facility in Holly Springs, NC, creating 355 jobs along the way. The new site in the Research Triangle area of North Carolina will bring a biologics drug substance manufacturing plant online to help the company continue to meet the production demands for its medicines.

“Amgen is investing in a technologically-advanced drug substance plant in North Carolina to support the expected increase in demand for our medicines,” Esteban Santos, executive vice president, Amgen. “Together with the previously announced advanced packaging plant in Ohio, we have committed to investing nearly $1 billion in new manufacturing capacity in the U.S.”

The Amgen facility in North Carolina will be built to exacting environmental standards, consistent with the company’s goal of achieving carbon neutrality, reduce water use by 40% and waste disposal by 75% by 2027. The facility also will support Amgen’s participation as a founding member of OneTen, a coalition of many of the world’s largest, best-known companies that aims collectively to hire one million Black Americans into well-paying jobs over the next ten years, with a specific focus on those without a four-year college degree.

"World-class companies like Amgen are very selective when they evaluate business locations and they only choose places that provide the best support for their operations,” said Governor Cooper. “Today’s decision proves once again that North Carolina remains a premier location for the most innovative biotech companies in the industry.”